KBKonstantinos G. Baroutis

Konstantinos G. Baroutis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantinos G. Baroutis has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ambient light drives verteporfin-induced protein cross-linking during standard laboratory sample processing

    by Konstantinos G. Baroutis, Victor San Martin C. Corrêa, Dimitrios Ntentakis, Toshio Narimatsu, Evangelos S. Gragoudas, Joan W. Miller, Lucy H. Young, Demetrios G. Vavvas

    Verteporfin (VP) is widely used as a light-independent pharmacologic inhibitor of the YAP-TEAD transcriptional complex, despite its potent photosensitizing properties. Here we show that VP-associated high–molecular–weight complexes and apparent depletion of key proteins on immunoblots can be substantially driven by ambient-light exposure during post-lysis handling, more than by light during cellular treatment. In this study, the hypothesis is tested independently using MEL270, HEK293, and MCF-7 cells treated with therapeutic and supra-therapeutic concentrations of VP under four systematically varied light/dark conditions. The results demonstrate that high-molecular-weight complex (HMWC) formation for p62, DIAP1, ROCK1, YAP, and phospho-YAP is driven principally by light exposure during sample processing rather than during cell treatment, occurs in cell-free lysates within 1 hour of ambient-light exposure, and is markedly attenuated by both N-acetylcysteine and L-histidine, consistent with contributions from both radical-mediated and singlet oxygen-mediated photochemistry. Notably, YAP and phospho-YAP are highly susceptible to photo-cross-linking, whereas transcription enhancer factor 1 (TEF1)/TEAD1 remains comparatively resistant, a pattern that mimics selective YAP-TEAD inhibition on standard immunoblots. In a single-experiment CCK-8 assay, viability was markedly lower under light than in darkness at 24 hours, an observation consistent with the immunoblot findings but requiring independent replication. These findings support the light-artifact hypothesis and may have implications for how preclinical data on VP are interpreted in the design of clinical investigations.

  • Sustained High-Intensity Lipophilic Statin Use and Risk of Age-Related Macular Degeneration

    by Maria Anna Bantounou, Maria Emfietzoglou, Tiarnán D.L. Keenan, Konstantinos G. Baroutis, Joan W. Miller, Demetrios G. Vavvas


  • Open Access

    Sustained proton-pump inhibitor exposure and incident age-related macular degeneration: a new-user, population-based cohort study

    by Maria Anna Bantounou, Maria Emfietzoglou, Konstantinos G Baroutis, Matthew R Starr, Joan W Miller, Demetrios G Vavvas

    Objective: Proton-pump inhibitors (PPIs) may disrupt lysosomal acidification, a pathway implicated in age-related macular degeneration (AMD) pathogenesis. We evaluated whether sustained PPI exposure increased the risk of incident AMD in older adults aged ≥60 years. Methods and analysis: This retrospective observational cohort study included adults aged ≥60 years with sustained PPI exposure, matched 1:1 to unexposed controls on demographics, overall health, healthcare utilisation, cardiometabolic factors. Participants were identified from electronic health records. Sustained PPI exposure was defined as ≥2 years of cumulative use within 3 years of the first prescription. Fine-Gray models treating death as a competing event estimated subdistribution hazard ratios (sHRs) for AMD within 10 years; cause-specific Cox models provided complementary HRs. Analyses included histamine H2-receptor antagonists (H2-antagonists) as a negative exposure control and active comparator. Results: Incident AMD occurred in 814/49 796 PPI exposed participants (1.64%) and 668/49 796 controls (1.34%) (overall sHR=1.24, 95% CI 1.12 to 1.38; p<0.001; HR=1.25, 95% CI 1.13 to 1.38, p<0.001). Proportional sHRs were non-constant; sHRs were 1.09 (95% CI 0.91 to 1.29) before 2.5 years and 1.33 (95% CI 1.17 to 1.51) thereafter. For non-exudative AMD, 640 PPI exposed (1.29%) and 510 unexposed (1.02%) participants developed disease (overall sHR=1.28, 95% CI 1.14 to 1.44; p<0.001, HR=1.29, 95% CI 1.14 to 1.44, p<0.001). Among those with non-exudative AMD, 190/2503 PPI-exposed participants (7.59%) and 179/2503 controls (7.15%) progressed to exudative AMD (sHR and HR=1.03, 95% CI 0.84 to 1.26; p=0.802 and p=0.801, respectively). No association was observed between H2-antagonists and AMD (sHR=1.02, 95% CI 0.88 to 1.19; p=0.784; HR=1.03, 95% CI 0.88 to 1.20, p=0.729). Results were consistent in the active-comparator analysis (reciprocal overall sHR=1.24, 95% CI 1.04 to 1.48; p=0.016; HR=1.25, 95% CI 1.05 to 1.49, p=0.012). Conclusion: Sustained PPI exposure was associated with a modestly higher AMD risk, whereas no association was observed with H2-antagonists. The consistency of the active-comparator findings supports the potential specificity of this association and warrants further investigation to determine its clinical implications.

  • Systemic Statin Use and Reduced Risk of Repeat Retinal Detachment Repair

    by Maria Anna Bantounou, Dimitra Foteinou, Konstantinos G. Baroutis, Maria Emfietzoglou, Darius D. Bordbar, Arthur R. Brant, Joan W. Miller, Demetrios G. Vavvas

  • Recent vaccination exposure and central serous chorioretinopathy

    by Maria Anna Bantounou, Dimitra Foteinou, Maria Emfietzoglou, Konstantinos G. Baroutis, Blake M. Hauser, Petros Petrou, Elizabeth J. Rossin, Joan W. Miller, Demetrios G. Vavvas

    Central serous chorioretinopathy (CSCR) is characterised by choroidal hyperpermeability and potential dysregulation of inflammatory cytokines. Because vaccination transiently activates cytokine pathways, we assessed whether vaccination is associated with incident CSCR. We performed a case-control study in the Mass General Brigham database among adults 18-60 years. CSCR cases were matched 4:1 to controls by demographics, systemic conditions relevant to vaccination likelihood or infection susceptibility, CSCR risk factors, healthcare utilisation and index month/year. Vaccination within 90 days before index was evaluated overall, by vaccine category, and by time window (1-10, 11-45, and 46-90 days before index); odds ratios (ORs) were estimated. Among 3 205 CSCR cases, 66 (2.1%) had recorded vaccination within 90 days before index compared with 232 (1.8%) of 12 753 controls (OR 1.14, 95% CI 0.86-1.50; P = 0.37). No associations were observed for influenza (OR 1.09, 95% CI 0.74-1.60; P = 0.67), COVID-19 (OR 1.00, 95% CI 0.37-2.66; P = 0.99), or tetanus-containing vaccines (OR 1.20, 95% CI 0.73-1.95; P = 0.48). Vaccination within 1-10 days before index was associated with higher odds of CSCR (OR 2.00, 95% CI 1.02-3.89; P = 0.043). Case-crossover analysis showed similar temporal clustering (OR 3.25, 95% CI 1.06-9.97; P = 0.039). Vaccination within 1-10 days before index was associated with higher odds of CSCR, although vaccination within 90 days was not. These findings do not support changes to vaccination practice for patients at risk of CSCR, but highlight the need for larger studies with complete vaccine capture to evaluate CSCR risk during the acute post-vaccination period.

  • Open Access

    Retinal detachment risk in a cohort of von Hippel-Lindau patients at a Major U.S. tertiary care facility

    by Konstantinos G. Baroutis, Gustavo Sakuno, Sandra Hoyek, Nimesh A. Patel, Joan W. Miller, Demetrios G. Vavvas


  • Ophthalmological manifestations in a cohort of Cowden syndrome patients in a large tertiary healthcare system

    by Konstantinos G. Baroutis, Sandra Hoyek, Victor S. M. C. Correa, Dimitrios P. Ntentakis, Nimesh A. Patel, Demetrios G. Vavvas

    Background/objectives Cowden syndrome (CS) is a rare genetic disorder caused by mutations in the PTEN gene associated with multisystem hamartomas and predisposition to malignancies. Although ocular involvement has been reported in case studies, systematic data are lacking. This study aimed to evaluate the prevalence, characteristics, and genotypic associations of ocular manifestations in CS patients within a large tertiary healthcare system. Subjects/methods We conducted a retrospective cohort study using the Mass General Brigham (MGB) Research Patient Data Registry, encompassing over 6 million patients from 2005 to 2024. Patients meeting clinical or genetic criteria for CS were identified. Ophthalmic findings, genotype–phenotype correlations, and clinical follow-up were extracted and analysed. A comprehensive literature review on CS-related ocular findings was performed to contextualize findings. Results Of the 6,026,276 patients in the RPDR, 144 patients carried the diagnostic codes for CS. After a manual review of all charts, 77 met the clinical or genetic criteria for CS. Of these, 17 (22%) underwent ophthalmologic evaluation, and 4 (5%) exhibited CS-related ocular findings, including retinal hamartoma, eyelid hemangioma, trichilemmoma, and a peripapillary hamartoma-like lesion. Most patients maintained excellent vision over a median follow-up of four and a half years. Retinal imaging was limited, with OCT and OCTA available in only one case. Genotype analysis revealed that truncating PTEN variants were more likely associated with central nervous system involvement. Literature review identified a broader spectrum of ocular anomalies in CS, underscoring phenotypic variability. Conclusions The prevalence of CS in a large US tertiary setting is 1.28/100,000. Ocular manifestations in CS are rare and typically benign, with preserved vision in most cases. However, variability in presentation and mutation types may influence the risk. Notably, three of the four patients with ocular findings, possibly associated with CS, carried truncating variants. The fourth was PTEN-positive, but the specific variant was not retrievable. Multicentre studies are warranted to better define the full ocular phenotype of CS and to guide screening recommendations.